Alnylam Pharmaceuticals, Inc. (ALNY) Stock Score, Valuation & Financial Research
Alnylam Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 38/100.
Quick answer for ALNY
Alnylam Pharmaceuticals, Inc. currently has a Wall Street Score of 38/100. The stored market price is $248.68. Its financial score is 39/100. Its valuation score is 4/100. The latest WSS change is -0.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What Alnylam Pharmaceuticals, Inc. does
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies i
ALNY financial snapshot
- Wall Street Score:
- 38/100
- Current price:
- $248.68
- Market capitalization:
- $33.28B
- Revenue:
- $4.80B
- Net income:
- $808.0M
- Free cash flow:
- $465.4M
- Cash:
- $1.71B
- Total debt:
- $1.27B
- EPS:
- 6.10
- P/E ratio:
- 40.8x
- Financial score:
- 39/100
- Valuation score:
- 4/100
- Revenue score:
- 50/100
What stands out
- Reported year-over-year revenue growth is +0.3%.
- Free cash flow is $465.4M, showing positive cash generation.
- The balance sheet shows $1.71B of cash versus $1.27B of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.5 points: ALNY decreased 0.5 points because Valuation declined by 4.3 points.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 39/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ALNY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.